Rebecca Louise Bromley

Rebecca Louise Bromley

Auto-generated profile, based on publicly available information

Rebecca Louise Bromley

Division of Neuroscience, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in The Lancet Neurology
Verified
Journal Article
Closed access
KMKimford J Meador
Kimford J Meador
GBGus A Baker
Gus A Baker
NBNancy Browning
Nancy Browning
MCMorris J Cohen
Morris J Cohen
RBRebecca L Bromley
Rebecca L Bromley
DLDavid W Loring
David W Loring

31 January 2013 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
RBRebecca Louise Bromley
Rebecca Louise Bromley
GMG. E. Mawer
G. E. Mawer
MBMaria Briggs
Maria Briggs
CCChristopher Cheyne
Christopher Cheyne
JCJill Clayton-Smith
Jill Clayton-Smith
GMG. Mawer
G. Mawer
The aim of this study was to compare the prevalence of diagnosed neurodevelopmental disorders in children exposed, in utero, to different antiepileptic drug treatments. A prospective cohort of women with epilepsy and a control group of women without epilepsy were recruited from antenatal clinics. The children of this cohort were followed longitudinally until 6 years of age (n=415). Diagnosis of a neurodevelopmental disorder was made independently of the research team. Multiple logistic regression analysis revealed an increase in risk of neurodevelopmental disorders in children exposed to monotherapy sodium valproate (VPA) (6/50, 12.0%; aOR 6.05, 95%CI 1.65 to 24.53, p=0.007) and in those exposed to polytherapy with sodium VPA (3/20, 15.0%; aOR 9.97, 95% CI 1.82 to 49.40, p=0.005) compared with control children (4/214; 1.87%). Autistic spectrum disorder was the most frequent diagnosis. No significant increase was found among children exposed to carbamazepine (1/50) or lamotrigine (2/30). An accumulation of evidence demonstrates that the risks associated with prenatal sodium VPA exposure include an increased prevalence of neurodevelopmental disorders. Whether such disorders are discrete or represent the severe end of a continuum of altered neurodevelopmental functioning requires further investigation. Replication and extension of this research is required to investigate the mechanism(s) underpinning the relationship. Finally, the increased likelihood of neurodevelopmental disorders should be communicated to women for whom sodium VPA is a treatment option.

27 January 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
GBGus A. Baker
Gus A. Baker
RBRebecca L. Bromley
Rebecca L. Bromley
MBMaria Briggs
Maria Briggs
CCChristopher P. Cheyne
Christopher P. Cheyne
MCMorris J. Cohen
Morris J. Cohen
LKLoretta Kerr
Loretta Kerr
Objective: To delineate the risk to child IQ associated with frequently prescribed antiepileptic drugs. Methods: Children born to women with epilepsy (n = 243) and women without epilepsy (n = 287) were recruited during pregnancy and followed prospectively. Of these, 408 were blindly assessed at 6 years of age. Maternal and child demographics were collected and entered into statistical models. Results: The adjusted mean IQ was 9.7 points lower (95% confidence interval [CI] −4.9 to −14.6; p < 0.001) for children exposed to high-dose (>800 mg daily) valproate, with a similar significant effect observed for the verbal, nonverbal, and spatial subscales. Children exposed to high-dose valproate had an 8-fold increased need of educational intervention relative to control children (adjusted relative risk, 95% CI 8.0, 2.5–19.7; p < 0.001). Valproate at doses <800 mg daily was not associated with reduced IQ, but was associated with impaired verbal abilities (−5.6, 95% CI −11.1 to −0.1; p = 0.04) and a 6-fold increase in educational intervention (95% CI 1.4–18.0; p = 0.01). In utero exposure to carbamazepine or lamotrigine did not have a significant effect on IQ, but carbamazepine was associated with reduced verbal abilities (−4.2, 95% CI −0.6 to −7.8; p = 0.02) and increased frequency of IQ <85. Conclusions: Consistent with data from younger cohorts, school-aged children exposed to valproate at maternal doses more than 800 mg daily continue to experience significantly poorer cognitive development than control children or children exposed to lamotrigine and carbamazepine.

2 December 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
RBR. L. Bromley
R. L. Bromley
GMG. Mawer
G. Mawer
JCJ. Clayton-Smith
J. Clayton-Smith
GBG. A. Baker
G. A. Baker

1 August 2014 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
KMKimford J. Meador
Kimford J. Meador
GBGus A. Baker
Gus A. Baker
NBNancy Browning
Nancy Browning
MCMorris J. Cohen
Morris J. Cohen
RBRebecca L. Bromley
Rebecca L. Bromley
DLDavid W. Loring
David W. Loring
Similar to alcohol, some antiepileptic drugs (AEDs) can cause widespread neuronal apoptosis in the immature animal brain.1-8 This effect is dose dependent, occurs at therapeutically relevant blood levels, and requires only brief exposure. The associated behavioral deficits in animals may be due more to dysfunction in the surviving neurons than to the loss of neurons.9 Consistent with these findings in animals, some AEDs have been associated with reduced cognitive abilities in children exposed in utero.10-14 Susceptibility of the immature brain to AED-induced apoptosis likely extends beyond birth, so concern has been raised that breastfeeding during maternal AED therapy might be harmful to the child. In contrast, known positive effects of breastfeeding exist for the child and mother.15 Therefore, a clinical dilemma presents as to the relative benefits and risks of breastfeeding during AED therapy. No animal data to date directly address this issue. In an ongoing prospective investigation of neurodevelopmental effects of AEDs on cognitive outcomes in children of mothers with epilepsy, the preliminary results at age 3 years found no difference in IQ for children who breastfed vs those who did not.16 However, IQ at age 6 years is more predictive of school performance and adult abilities.17 Furthermore, additional cognitive domains can be assessed at age 6 years vs at age 3 years. So, we examined cognitive outcomes in our cohort at age 6 years.

7 November 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
JWJennifer Weston
Jennifer Weston
RBRebecca Bromley
Rebecca Bromley
CJCerian F Jackson
Cerian F Jackson
NANaghme Adab
Naghme Adab
JCJill Clayton-Smith
Jill Clayton-Smith
AMAnthony G Marson
Anthony G Marson